Covid-19 Ivermectin

mosseero

fizik´alc
3. sep 2007
19.212
9.451
113
kod Džej-Zija
Posnela je Zoom pogovor avtorja meta študije, v katerem ji je priznal, da so zunanji avtorji in sponzorji vplivali na rezultat študije meta analize študij o Ivermectinu, na podlagi katere je bil Ivermectin sesut.

Podobno kot s HidroxyChloroquinom:

Covid-19: Lancet retracts paper that halted hydroxychloroquine trials​



Lancet retraction:


Ne vem, kaj vam ni jasno.
Kako pa lahko zunanji avtorji vplivajo na meta študijo o ivermektinu? Saj veš, kaj je meta študija, kajne? Razen če je zadeva v celoti potvorjena, kar se da s statistično analizo lepo preveriti. Ker meta študija ni nič drugega kot statistična analiza posamičnih člankov.
 
  • Všeč mi je
Reactions: bizi

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113
Kako pa lahko zunanji avtorji vplivajo na meta študijo o ivermektinu? Saj veš, kaj je meta študija, kajne? Razen če je zadeva v celoti potvorjena, kar se da s statistično analizo lepo preveriti. Ker meta študija ni nič drugega kot statistična analiza posamičnih člankov.
Zakaj si nisi ogledal tega video posnetka, da to sprašuješ?

 

mosseero

fizik´alc
3. sep 2007
19.212
9.451
113
kod Džej-Zija
Ker se mi ne da gledat YT linkov. Me niti ne zanima, kakšni so bili pritiski in ponudbe. Zanima me samo, kako je študija pofejkana. Ker to konsistentnost lahko bolj ali manj vsak statistik z dostopom do neta preveri.
 

BLABLABLA

Guru
28. sep 2007
2.208
699
113

Novartis/Lek je v 2020 doniral Hidroksiklorokinin za zdravljenje ....... hmmm....Kovid 19....

Zgoraj je uradna objava
 
  • Wow
  • Všeč mi je
Reactions: javr in jendomen

jest5

Guru
18. avg 2007
25.162
-8.273
113
Takrat se ni nič vedelo o učinkovitosti. Testirali so dosti zadev, med drugim tudi to. Kasneje se je izkazalo, da pač ne deluje.
 
  • Všeč mi je
Reactions: Gavran

jest5

Guru
18. avg 2007
25.162
-8.273
113
:valjamse: :valjamse: :valjamse: :valjamse: :valjamse:


Spet ta stran powered by FLCCC šarlatani

:valjamse::valjamse::valjamse:


Btw nisi povedal zadnjič, kako je kaj z odstranjevanjem dokazano ponarejenih ali pomanjkljivih "študij" s tega, ter ivrca seznama?
 

jest5

Guru
18. avg 2007
25.162
-8.273
113
Ti si prilepil že en kup sranja ja. Sranja, ki ga ponavadi niti sam ne razumeš.

Btw, pri sars-cov-1 je bilo vsega skupaj potrjenih primerov toliko, kot jih je sedaj v eni sami dobro izvedeni študiji. Okoli 8000.
 

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113

Treatments for COVID-19 incorporating hot-button drugs such as ivermectin and hydroxychloroquine are being secretly adopted by National Football League teams, according to one of the NFL's biggest stars.
 
  • Haha
Reactions: Ytbnd

damirj

Guru
9. maj 2012
4.769
2.021
113
Ker je tebi sedaj to referenca. Ker iščeš vsako nitko, da le lahko napišeš nekaj v zagovor iverke, pa čeprav je butasto in skrajno sarkastično do amena.
 

luka51

Guru
16. avg 2007
13.836
5.081
113
Ja ker mesenger je tisti ki nasere to vsebino.
Sicer pa tebi je itak vseeno kdo je mesenger ker vsebina je 100% legit.
To kaj Rogan reče je tudi brez dvomov resnica. ni zaj tu nekaj za dvomit ne.
In če top športnik nekaj reče potem do definitivno drži.
 

AndY1

Guru
Osebje foruma
18. sep 2007
22.031
4.047
113
Najnovejša študija.

Ivermectin Prophylaxis Used for COVID-19 Reduces COVID-19 Infection and Mortality Rates: A City-Wide, Prospective Observational Study of 220,517 Subjects Using Propensity Score Matching.​



Abstract​

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both COVID-19 infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajai, a Southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program which occurred between July 2020 to December of 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit in order to enroll in the program and to compile baseline, personal, demographic and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken 2 consecutive days every 15 days at a dose of 0.2mg/kg/day. In cases where a participating citizen of Itajai became ill with COVID-19, they were recommended to not use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score matched (PSM) by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without use of propensity score matching. Results: A total of 220,517 subjects were included in the analysis; 133,051 (60.3%) regular ivermectin users and 87,466 (39.7%) non-users. Using PSM, two cohorts of 3,034 subjects suffering COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality [25 (0.8%) versus 79 (2.6%) among ivermectin non-users; risk ratio (RR), 0.32; 95% confidence interval (CI), 0.20 – 0.49; p < 0.0001]. When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95%CI 0.19 – 0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95%CI, 0.31 – 0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95%CI 023 – 0.66; p < 0.0001). Conclusion: In this large, propensity score matched study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.
 

Ted

Guru
8. sep 2007
1.682
576
113
Najnovejša študija.

Ivermectin Prophylaxis Used for COVID-19 Reduces COVID-19 Infection and Mortality Rates: A City-Wide, Prospective Observational Study of 220,517 Subjects Using Propensity Score Matching.​



Abstract​

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both COVID-19 infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajai, a Southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program which occurred between July 2020 to December of 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit in order to enroll in the program and to compile baseline, personal, demographic and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken 2 consecutive days every 15 days at a dose of 0.2mg/kg/day. In cases where a participating citizen of Itajai became ill with COVID-19, they were recommended to not use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score matched (PSM) by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without use of propensity score matching. Results: A total of 220,517 subjects were included in the analysis; 133,051 (60.3%) regular ivermectin users and 87,466 (39.7%) non-users. Using PSM, two cohorts of 3,034 subjects suffering COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality [25 (0.8%) versus 79 (2.6%) among ivermectin non-users; risk ratio (RR), 0.32; 95% confidence interval (CI), 0.20 – 0.49; p < 0.0001]. When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95%CI 0.19 – 0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95%CI, 0.31 – 0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization rate was 67% (RR, 0.33; 95%CI 023 – 0.66; p < 0.0001). Conclusion: In this large, propensity score matched study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

Morda bi lahko na to temo Štrukelj več povedal, pa žal ne bo ker so ga anticepilci fizično napadli...
 

damirj

Guru
9. maj 2012
4.769
2.021
113
Je zmanjkalo študij iz Indije in Egipta, sedaj je na sporedu Brazilija? Sem na hitro prebral in mi izgleda eno tipično manipuliranje s podatki. Že naslov je zavajujoč, ker namreč niso izdvedli te študije na 220000 ljudeh, kot piše v naslovu. Če je že naslov zavajujoč, publicističen, potem tudi v vsebino ne bom verjel 100%.